MediciNova Stock Discussion

$MediciNova (MNOV.US)$Reuters
13 mins ago
Medicinova Presents Study Update and Interim Analysis of Phase 2/3 Clinical Trial of Mn-166 (Ibudilast) in ALS (Combat-ALS Clinical Trial) at the 35TH International Symposium on ALS/Mnd
MediciNova Inc - Positive Correlations Observed Between 6-Month and 12-Month Data

$Mercurity Fintech (MFH.US)$ $Freightos (CRGO.US)$ $1847 Holdings (EFSH.US)$ $MediciNova (MNOV.US)$ $Despegar.com (DESP.US)$ $NextPlat (NXPL.US)$ $Legacy Education (LGCY.US)$ $Gain Therapeutics (GANX.US)$ $Red Cat Holdings (RCAT.US)$ $Siyata Mobile (SYTA.US)$ $Innovation Beverage Group (IBG.US)$ $Greenidge Generation (GREE.US)$ $The Arena Group (AREN.US)$
📊⚡️📊

$MediciNova (MNOV.US)$ Reuters· 6 mins ago
MediciNova Inc - Patent Is Expected to Expire No Earlier Than May 26, 2042

$MediciNova (MNOV.US)$
MediciNova Receives Notice of Allowance from United States Patent and Trademark Office for New Patent Covering MN-001 for Triglyceride Synthesis in the Liver

$MediciNova (MNOV.US)$
MediciNova Given Notice of Monetary Damages Due Under Patent Settlement of Sanofi-Novartis
MediciNova (NASDAQ: MNOV) announced it will receive monetary damages following the settlement of Sanofi-Novartis litigation. The company plans to use this non-dilutive fundingto support ongoing clinical development programs, particularly focusing on their late-stage pipeline targeting inflammatory, metabolic, and neurodegenerative diseases. The settlement validates MediciNova's in...